



Pr pdp-Levetiracetam

ORAL SOLUTION/IV SOLUTION
100 mg / mL

The #1 neurologist- prescribed AED in Canada*

NEW

NOW AVAILABLE IN
AN IV SOLUTION AND
AN ORAL SOLUTION

Rx

*only by Pendopharm
pdp-Levetiracetam*



First oral solution of levetiracetam in Canada with an indication for the pediatric population.

Indications and clinical use:

Adults

pdp-levETIRAcetam (levetiracetam) Oral Solution and pdp-levETIRAcetam (levetiracetam) for Injection are indicated as adjunctive therapy in the management of patients with epilepsy who are not satisfactorily controlled by conventional therapy.

pdp-levETIRAcetam for Injection is for intravenous use only as an alternative for patients when oral administration is temporarily not feasible.

Pediatrics

- pdp-levETIRAcetam for Injection** is indicated as adjunctive therapy in the treatment of:
- partial-onset seizures with or without secondary generalization in **adolescents, children, and infants from 1 month of age with epilepsy.**
 - myoclonic seizures in **adolescents from 12 years of age with juvenile myoclonic epilepsy.**
 - primary generalized tonic-clonic seizures in **adolescents from 12 years of age with idiopathic generalized epilepsy.**

pdp-levETIRAcetam for Injection is for intravenous use only as an alternative for patients when oral administration is temporarily not feasible.

For more information:

Please consult the Product Monograph at <https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=98048> for important information relating to adverse reactions, drug interactions, and dosing information that has not been discussed in this piece. The Product Monograph is also available by calling us at 1-888-550-6060.


AED: antiepileptic drug

*IMS Data. Data from October 1, 2018, to September 30, 2019.



Think simple. Think Solution. >

COVID-19: Latest updates for neurologists



[Learn more](#)



DIN 02442256

**The only Rx
vitamin D 2,000 IU**
marketed in Canada

- **Same price** as 2 x 1,000 IU
- **Covered by most private insurance plans, RAMQ¹ & NIHB²**
- **Made in Canada** and marketed by a **Canadian company**



For more info/to order:

daretoprevent.com
Password: luxad123

**Consider Luxa-D for your patients living
with multiple sclerosis (MS)**

People living with MS are at increased risk for
osteoporosis, falls, and bone fractures³



® Registered trademark of Orimed Pharma. Used under license.
© 2019 Orimed Pharma Inc. All rights reserved.
1310 Nobel Street, Boucherville, Quebec, J4B 5H3 | Toll free: 1 866 399-9091



Indications and clinical use:

LUXA-D 2000 IU is indicated for the:

- treatment and prevention of vitamin D deficiency;
- management and prevention of primary and corticosteroid-induced osteoporosis, in conjunction with calcium;
- treatment of refractory rickets (vitamin D resistant rickets);
- treatment of familial hypophosphatemia;
- treatment of hypoparathyroidism.

Contraindications:

LUXA-D 2000 IU should not be used in patients with:

- hypercalcemia and/or hypercalciuria;
- nephrolithiasis (renal calculi);
- severe renal impairment;
- malabsorption syndrome;
- abnormal sensitivity to the toxic effects of Vitamin D;
- hypervitaminosis D.

Relevant warnings and precautions:

- Administration of excessive doses may lead to hypervitaminosis D
- Interindividual variation in dose may lead to chronic toxicity
- Periodic monitoring of serum calcium, phosphate, magnesium, and alkaline phosphatase is recommended
- Avoid use in excess of recommended dietary allowance in pregnant and nursing women

For more information:

Please consult the Prescribing Information at https://pdf.hres.ca/dpd_pm/00051659.PDF for important information relating to adverse reactions, drug interactions, and dosing information which have not been discussed in this piece.

References

1. Régie de l'assurance maladie du Québec (RAMQ). List of Medications. July 10, 2019. Accessed on January 4, 2019.
2. Non-Insured Health Benefits: Drug benefit list. October 2019. Accessed on January 4, 2019.
3. MS Society of Canada. MS Society of Canada Recommendations on Vitamin D in MS. November 2018. Accessed on February 2, 2020.

Cambridge Core
For further information about this journal
please go to the journal website at:
[cambridge.org/cjn](https://www.cambridge.org/cjn)

CAMBRIDGE
UNIVERSITY PRESS